Neuschwander-Tetri – Advisory Committees or Review Panels: Boehri

Neuschwander-Tetri – Advisory Committees or Review Panels: Boehring-er-Ingelheim selleck chemicals llc Stephen H. Caldwell – Advisory Committees or Review Panels: Vital Therapy; Consulting: Wellstat diagnostics; Grant/Research Support: Genfit, Gilead Sciences Kris V. Kowdley – Advisory Committees or Review Panels: AbbVie, Gilead, Merck, Novartis, Trio

Health, Boeringer Ingelheim, Ikaria, Janssen; Grant/Research Support: AbbVie, Beckman, Boeringer Ingelheim, BMS, Gilead Sciences, Ikaria, Janssen, Merck, Mochida, Vertex Mary E. Rinella – Advisory Committees or Review Panels: Gilead The following people have nothing to disclose: Zurabi Lominadze, Michael Charl-ton Background: We already reported that incretin based medicine, such as GLP-1 analogues or DPP-4 inhibitors, leading to improve not only glycaemic control but

also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM). However, the features and differences between GLP-1 analogues and DPP-4 inhibitors are not well known. Aims: The aim of this study is to elucidate the features and differences of each incretin based medicine in NAFLD Selleck Galunisertib patients with T2DM compared to conventional treatments such as diet therapy, exercise therapy, and other pharmacological treatments including pioglitazone. Methods: We retrospectively enrolled consecutive 209 Japanese NAFLD patients with T2DM and divided these patients into three groups (GLP-1 group, DPP-4 group, and controls). We compared the base line characteristics and the changes of laboratory data and body weight among the three groups aminophylline at the end of follow-up. We also assessed the significant factors which contributed to rapid normalization of serum ALT level using multivariate Cox proportional hazard models. Results: There

were 41 patients treated with incretin based medicine (GLP-1 group), 88 patients treated with DPP-4 inhibitors (DPP-4 group), and 80 patients treated with conventional therapies (controls). At the end of follow-up, serum ALT level, fast blood glucose level, and HbA1c level significantly improved among the three groups. Although the body weight significantly decreased in incretin based medicine group (83.3 kg to 78.9 kg, P < 0.01), the body weight did not change in other two groups. The cumulative normalization rates of serum ALT level significantly differed among the three groups (P < 0.01); 20.9%, and 64.5% at 1 year, and 2 years in GLP-1 group, 31.7%, and 46.8% in DPP-4 group, and 23.4%, and 30.5% in the controls, respectively. Multivariate analysis indicated that administration of GLP-1 analogues (OR 0.61, P = 0.04), and age (per 1 year, OR 1.03, P = 0.

Comments are closed.